Ilevbare Grace A, Liu Haoyu, Pereira Junia, Edgar Kevin J, Taylor Lynne S
Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana.
Mol Pharm. 2013 Sep 3;10(9):3392-403. doi: 10.1021/mp400228x. Epub 2013 Jul 30.
The formation of colloidal drug aggregates of lipophilic drugs is thought to be of relevance for the oral delivery of poorly water-soluble drugs. In this study, the underlying basis for colloid formation from amorphous solid dispersions and the impact of additives on colloidal stability were evaluated. A relationship was found between the concentration at which colloidal droplets formed upon dissolution of an amorphous solid dispersion and the liquid-liquid phase separation (LLPS) transition concentration, whereby the latter is related to the theoretical amorphous "solubility" value. The composition of the dispersed phase in ritonavir-polymer-water solutions was confirmed to be a noncrystalline, ritonavir-rich droplet phase. Additives were found to impact the size, stability, and crystallization behavior of the colloidal phase. In general, charged additives reduced the kinetics of droplet coalescence, but had a variable effect on crystallization kinetics, either promoting or inhibiting crystallization. Through proper selection of formulation components, it thus appears possible to promote the formation of ∼ 250-350 nm colloidal droplets of ritonavir following dissolution of an amorphous solid dispersion, and to inhibit coalescence and crystallization from these two-phase supersaturated solutions.
亲脂性药物的胶体药物聚集体的形成被认为与难溶性药物的口服给药相关。在本研究中,评估了由无定形固体分散体形成胶体的潜在基础以及添加剂对胶体稳定性的影响。发现无定形固体分散体溶解时形成胶体液滴的浓度与液-液相分离(LLPS)转变浓度之间存在关系,其中后者与理论无定形“溶解度”值相关。证实利托那韦-聚合物-水溶液中分散相的组成是富含利托那韦的非晶态液滴相。发现添加剂会影响胶体相的大小、稳定性和结晶行为。一般来说,带电添加剂会降低液滴聚并的动力学,但对结晶动力学有可变影响,既可以促进结晶也可以抑制结晶。因此,通过适当选择制剂成分,似乎有可能在无定形固体分散体溶解后促进形成约250-350 nm的利托那韦胶体液滴,并抑制这些两相过饱和溶液中的聚并和结晶。